The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Treating MCL in resource-limited settings: BTK inhibitors and anti-CD20 antibodies as leading agents
Elise Chong, MD, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, discusses the key frontline treatments for mantle cell lymphoma (MCL) in resource-limited settings, highlighting BTK inhibitors (BTKis) and anti-CD20 antibodies, particularly rituximab, as the most important agents to have access to. Dr Chong explains that rituximab-based and BTKi-based approaches have demonstrated advantages over R-CHOP, while rituximab maintenance has been associated with a survival benefit. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so I think that you’ve seen now some of the newer randomized data presented in 2024 that R-CHOP is clearly inferior to either a bendamustine-rituximab-based approach or a BTK-rituximab-based approach, at least with ibrutinib. And so I think that we’ve learned that at least two drugs that if you can have access to them are really important to have are rituximab and a BTK, and that still is borne out in the TRIANGLE data as well, or a CD20 antibody, if not rituximab...
Yeah, so I think that you’ve seen now some of the newer randomized data presented in 2024 that R-CHOP is clearly inferior to either a bendamustine-rituximab-based approach or a BTK-rituximab-based approach, at least with ibrutinib. And so I think that we’ve learned that at least two drugs that if you can have access to them are really important to have are rituximab and a BTK, and that still is borne out in the TRIANGLE data as well, or a CD20 antibody, if not rituximab. And I think the rest of that, and we also know that rituximab maintenance has a survival benefit, so I think that really the two most active drugs for frontline mantle cell lymphoma right now are BTKs with a CD20 antibody.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
